A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy Meeting Abstract
| Authors: | Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; Lansigan, F.; Pu, J. J.; Skarbnik, A. P.; Fonseca, G. A.; Dorsey, C.; Prak, E. L.; Paskalis, D.; Sportelli, P.; Miskin, H. P.; Brander, D. M. |
| Abstract Title: | A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 407s |
| Language: | English |
| ACCESSION: | WOS:000442916002600 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.7530 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7530 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
